Results 151 to 160 of about 170,196 (315)

Personalized Treatment Selection for Digital Eating Disorder Interventions: A Proof‐of‐Concept for the Personalized Advantage Index

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Although a range of evidence‐based treatments for eating disorders exist, treatment response varies substantially. The ability to match individuals to a treatment which they are most likely to benefit from may help improve treatment efficiency and therapeutic outcomes.
Zoe McClure, Matthew Fuller‐Tyszkiewicz, Mariel Messer, Jake Linardon   +3 more
wiley   +1 more source

Parenteral morphine and oxycodone mixtures administered in specialised palliative and hospice care units: A retrospective medical record review

Palliative Care and Social Practice
Background: Continuous subcutaneous infusions combining several drugs are routinely used in palliative care, particularly for severe pain management. Parenteral administration routes, however, have been found to be prone to errors.
Ilona Niittynen, Jonna Juvankoski, Kaisla Mannerla, Hanna M. Tolonen, Marja Airaksinen, Maria Rautamo   +5 more
doaj   +1 more source

Interventional pharmacotherapy

BMJ, 2003
Roger, Philipp, Ever D, Grech
openaire   +3 more sources

Response to comment on "International consensus recommendations for the use of prolonged-infusion β-lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists".

Click on the Resource Link to access the article (may not be free).https://doi.org/10.1002/phar ...
Roberts, Jason A, Jang, Soo Min, Lodise, Thomas, Zuppa, Athena, Downes, Kevin J, Alshaer, Mohammad H, Bassetti, Matteo, Kuti, Joseph L, Bonomo, Robert A, Jorgensen, Sarah, Hong, Lisa T, FakhriRavari, Alireza, Young, David C, Gilchrist, Mark, Tängdén, Thomas, Scheetz, Marc H, Abdul-Mutakabbir, Jacinda C   +16 more
core   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Current Pharmacotherapy of Epithelial Ovarian Cancer

Epithelial ovarian cancer is the most common and deadliest form of ovarian cancer, often diagnosed late because it progresses with few or no symptoms.
Umeh, Tracy Chinenye
core  

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Cardiovascular pharmacotherapy [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2017
openaire   +2 more sources

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Association Between Hypnotics and Glycemic Variability Assessed by Continuous Glucose Monitoring Under Real-Life Conditions in Patients With Type 2 Diabetes: A Cross-Sectional Study

Journal of Diabetes Research
Taichi Muramatsu, Miku Otsuka, Daisuke Yamamuro, Mikan Yamanouchi, Saaya Fujisaka, Akifumi Kushiyama, Takako Kikuchi   +6 more
doaj   +1 more source